Podcasts about Inflammatory

Chronic disease can have a devastating impact on your life. It can be all too easy to give up and accept the new normal, but there are often ways to regain control. ⁠Dr. Terry Wahls⁠ not only found a way to slow the progression of her own disease, but she also developed a protocol to help others do the same. Dr. Wahls is recognized worldwide for her protocol which is transforming the lives of countless people. She is a clinical professor at the University of Iowa. Dr. Wahls conducts clinical trials into the efficacy of therapeutic lifestyle to treat multiple sclerosis-related symptoms. She is the author of ⁠The Wahls Protocol⁠ as well as her revolutionary ⁠cookbook⁠. In part one of our conversation, Dr. Wahls shares the specifics of her protocol. Before her diagnosis of multiple sclerosis, Dr. Wahls was an incredibly active woman. After seeking out various aggressive treatments for her condition, Dr. Wahls realized that it was up to her to take control of her health. Dr. Wahls came to realize that redesigning a paleo-diet to focus on the right nutrients could make a difference. Within months, she experienced massive improvements and is as active as ever. A key part of her recovery centers on feeding the mitochondria. With her redesigned diet, Dr. Wahls is able to better make use of the nutritional compounds that would otherwise be in supplements. Eating lots of green leafy, colorful, and sulfur-rich vegetables is a key part of this. Likewise, there are foods to avoid, particularly gluten and casein. Changing your habits and diet is easier said than done. Most practitioners know the struggle of patient compliance. Dr. Wahls shares some great advice for helping to motivate patients so that they can better take ownership of their health. Have you changed your diet in response to chronic disease? Tell me how it's going in the comments on the episode page!   My ⁠Your Longevity Blueprint course⁠ is currently 50% off to celebrate the launch of the podcast PLUS I'm throwing in a free personalized consultation!    In this episode: How a lack of success with conventional treatments led Dr. Wahls to develop her own MS protocol The role of mitochondria in maintaining cellular health The foods that make up the Wahls Protocol A great healthy recipe for meat lovers Inflammatory foods to avoid Why changing our diets is often so difficult Links & Resources: Use code COQ10 to get 10% off ⁠⁠⁠COQ10 Use code ENERGY to get 10% off ⁠⁠⁠MITOCHONDRIAL COMPLEX ⁠⁠⁠⁠Sinus Support Use code GLUTATHIONE to get 10% off ⁠GLUTATHIONE Multiple Sclerosis and NeuroImmune Summit 2.0: ⁠Learn more here⁠ ⁠Follow Dr. Terry Wahls online⁠ Follow Dr. Wahls on ⁠Facebook⁠ | ⁠Pinterest⁠ | ⁠Twitter⁠ | ⁠YouTube⁠   ⁠The Wahls Protocol⁠ ⁠The Wahls Protocol Cooking for Life⁠ ⁠Linus Pauling Institute⁠   ⁠Get your copy of the Your Longevity Blueprint book and claim your bonuses here⁠ ⁠Find Dr. Stephanie Gray and Your Longevity Blueprint online⁠   Follow Dr. Stephanie Gray on ⁠Facebook⁠ | ⁠Instagram⁠ | ⁠Youtube⁠ | ⁠Twitter⁠ | ⁠LinkedIn⁠ ⁠Integrative Health and Hormone Clinic⁠   ⁠Podcast Production by the team at Counterweight Creative⁠ 

Sleep detoxifies our brains! Refined sugars, junk food, and late-night snacking can interfere with sleep. If you want better sleep, eat earlier in the day. For the best sleep, have your last meal around 5:00 p.m. If you're waking at night to urinate, intermittent fasting and a low-carb diet can help. Inflammatory foods, such as grains, can also interfere with your sleep. High carbohydrate diets increase your need for vitamin B1, which reduces anxiety and tension.Kefir contains probiotics that can build up serotonin, which turns into melatonin, the sleep hormone. L. reuteri yogurt also contains helpful probiotics to improve sleep. Consume ½ cup daily; it doesn't have to be before bed.Try the following tips for better sleep to help you wake up early feeling refreshed and energized!

Sleep detoxifies our brains! Refined sugars, junk food, and late-night snacking can interfere with sleep. If you want better sleep, eat earlier in the day. For the best sleep, have your last meal around 5:00 p.m. If you're waking at night to urinate, intermittent fasting and a low-carb diet can help. Inflammatory foods, such as grains, can also interfere with your sleep. High carbohydrate diets increase your need for vitamin B1, which reduces anxiety and tension.Kefir contains probiotics that can build up serotonin, which turns into melatonin, the sleep hormone. L. reuteri yogurt also contains helpful probiotics to improve sleep. Consume ½ cup daily; it doesn't have to be before bed.Try the following tips for better sleep to help you wake up early feeling refreshed and energized:•Sleep in a 65 to 68 degree room•If you have cold feet at night, try sleeping with warm socks•Plants in the room can help oxygenate the space and improve sleep•The darker the environment, the better Light inhibits melatonin. Blue light from your computer or phone stimulates energy, while infrared lighting helps you wind down. Around 50% of the sun's rays are infrared and can penetrate several inches into the body. Infrared light helps you make vitamin D, which is vital for sleep and increasing melatonin. Since culture has pushed us away from sun exposure, sleep quality has declined. Alcohol will make you feel tired, but it interferes with deep sleep. Caffeine, tea, coffee, and chocolate act as stimulants and prevent sleep. Increase exercise to improve sleep. Stretching and massage can also help you relax. Here are a few more deep sleep tips that can significantly improve sleep quality:•Sleep on your right side•Focus on nose breathing •Reduce stress for better sleep•Ensure adequate sodium intake to maintain healthy cortisol levels •Increase potassium intake •Consume magnesium glycinate powder 1 hour before bed •Sound machine •Binaural beats •Use essential oils (Spikenard, vetiver)Dr. Eric Berg DC Bio:Dr. Berg, age 60, is a chiropractor who specializes in Healthy Ketosis & Intermittent Fasting. He is the author of the best-selling book The Healthy Keto Plan, and is the Director of Dr. Berg Nutritionals. He no longer practices, but focuses on health education through social media.

Most people think dental problems only affect their mouth, but that's where they're dead wrong. After my conversation with Dr. Jigar Gandhi, I'm convinced we've been missing a massive piece of the health optimisation puzzle, and this is where biological dentistry comes in. When I had my infected tooth removed, my shoulder pain, lung catch, and toe numbness disappeared within 48 hours, because each tooth connects to specific organ systems through 5,000-year-old meridian mapping. Your mouth is the gateway to chronic infections that can trigger autoimmune diseases, brain fog, and systemic inflammation throughout your entire body.  Join the Ultimate Human VIP community: https://bit.ly/4ai0Xwg Connect with Dr. Jigar Gandhi: Website: http://bit.ly/4l7hSX3 Website: http://bit.ly/3Goflsn YouTube: http://bit.ly/44EUv1c Instagram: http://bit.ly/4ezmKSy TikTok: http://bit.ly/4lfLIJe Find Authorised Biological Dentists:  http://bit.ly/4ntxxBD Study on Root Canals Causing Breast Cancer:  http://bit.ly/4lxgP2o IAOMT Position Paper on Human Jawbone Cavitations: http://bit.ly/3ZSDrlO Thank you to our partners: H2TABS - USE CODE “ULTIMATE10” FOR 10% OFF: https://bit.ly/4hMNdgg BODYHEALTH - USE CODE “ULTIMATE20” FOR 20% OFF: http://bit.ly/4e5IjsV BAJA GOLD - USE CODE "ULTIMATE10" FOR 10% OFF: https://bit.ly/3WSBqUa EIGHT SLEEP - SAVE $350 ON THE POD 4 ULTRA WITH CODE “GARY”: https://bit.ly/3WkLd6E COLD LIFE - THE ULTIMATE HUMAN PLUNGE: https://bit.ly/4eULUKp WHOOP - GET 1 FREE MONTH WHEN YOU JOIN!: https://bit.ly/3VQ0nzW MASA CHIPS - GET 20% OFF YOUR FIRST ORDER: https://bit.ly/40LVY4y VANDY - USE CODE “ULTIMATE20” FOR 20% OFF: https://bit.ly/49Qr7WE AION - USE CODE “ULTIMATE10” FOR 10% OFF: https://bit.ly/4h6KHAD A GAME - USE CODE “ULTIMATE15” FOR 15% OFF: http://bit.ly/4kek1ij HAPBEE - FEEL BETTER & PERFORM AT YOUR BEST: https://bit.ly/4a6glfo CARAWAY - USE CODE “ULTIMATE” FOR 10% OFF: https://bit.ly/3Q1VmkC HEALF - GET 10% OFF YOUR ORDER: https://bit.ly/41HJg6S BIOPTIMIZERS - USE CODE “ULTIMATE” FOR 10% OFF: https://bit.ly/4inFfd7 RHO NUTRITION - USE CODE “ULTIMATE15” FOR 15% OFF: https://bit.ly/44fFza0 GENETIC TEST: ⁠https://bit.ly/3Yg1Uk9 Watch  the “Ultimate Human Podcast”: YouTube: https://bit.ly/3RPQYX8 Podcasts: https://bit.ly/3RQftU0 Connect with Gary Brecka: Instagram: https://bit.ly/3RPpnFs TikTok: https://bit.ly/4coJ8fo X.com: https://bit.ly/3Opc8tf Website: https://bit.ly/4eLDbdU Merch: https://bit.ly/4aBpOM1 Newsletter: https://bit.ly/47ejrws Ask Gary: https://bit.ly/3PEAJuG Timestamps: 00:00 Intro 04:14 What is an Organ? 07:15 Symptoms and Testings with Biological Dentistry 12:23 Inflammatory markers 15:00 Tooth removal and microscopic examination 17:02 Addressing Optimal Health with Biological Dentistry 19:26 Tooth removal procedure 21:08 Dental Medicine Taking the Spotlight 24:12 After a Root Canal 28:59 Outcomes after Biological Dentistry Procedures 30:54 Chronic and Autoimmune Disease Symptoms 39:27 Testimonials from Dr. Gandhi's Patients: http://bit.ly/4kBGGpj 46:26 Recognizing the Starting Point of the Existence of Diseases 51:38 Importance of Proper Oral Care Routine  56:41 When to See a Biological Dentist? 1:00:05 What does it mean to you to be an “Ultimate Human?” The Ultimate Human with Gary Brecka Podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast or materials linked from this podcast is at the user's own risk. The Content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they may have and should seek the assistance of their health care professionals for any such conditions. Learn more about your ad choices. Visit megaphone.fm/adchoices

Host: Darryl S. Chutka, M.D. Guests: David H. Bruining, M.D., and Nayantara Coelho-Prabhu, M.B.B.S. An early diagnosis of inflammatory bowel disease is important in preventing long-term complications. Prompt treatment can improve quality of life, reduce the likelihood of hospitalizations, and help maintain remissions. However, establishing a diagnosis is often challenging due to the nonspecific and fluctuating nature of symptoms. Inflammatory bowel disease can also mimic other GI conditions. In addition, diagnostic confirmation usually requires a combination of blood tests, imaging, endoscopy, and histological analysis, making the process both time consuming and complex.  The topic for today's podcast is “Diagnosing Inflammatory Bowel Disease and Monitoring Modalities” and my guests are David H. Bruining, M.D., and Nayantara Coelho-Prabhu, M.B.B.S., from the Division of Gastroenterology and Hepatology at the Rochester campus of the Mayo Clinic. https://ce.mayo.edu/content/mayo-clinic-talks-inflammatory-bowel-disease   Connect with us and learn more here: https://ce.mayo.edu/online-education/content/mayo-clinic-podcasts   

Entertainment reporter Peter Ford has shed light on US President Donald Trump's "war path" with American TV network CNN.See omnystudio.com/listener for privacy information.

Dr. Jessica Eccles surveys the growing body of research that points to an association between neurodivergence, joint hypermobility, chronic pain, and anxiety. Learn why certain physical symptoms are more common in people with ADHD and autism, and about treatment options. Joint Hypermobility, Pain, & Neurodivergence: Additional Resources Read: ADHD at the Center: A Whole-Life, Whole-Person Condition Read: How ADHD Can Intensify Physical Health Conditions Read: ADHD, Autism, and Neurodivergence Are Coming Into Focus Read: The Gut-Brain Axis Could Accelerate Autism Understanding Watch: The Surprising Association Between ADHD & Inflammation Access the video and slides for podcast episode #560 here: https://www.additudemag.com/webinar/joint-hypermobility-adhd-autism-inflammation-pain/ This episode is sponsored by the podcast Sorry, I Missed This. Search for “Sorry I Missed This” in your podcast app or find links to listen at https://lnk.to/sorryimissedthisPS. Thank you for listening to ADDitude's ADHD Experts podcast. Please consider subscribing to the magazine (additu.de/subscribe) to support our mission of providing ADHD education and support.

Dr. Allison Zibelli and Dr. Rebecca Shatsky discuss advances in breast cancer research that were presented at the 2025 ASCO Annual Meeting, including a potential new standard of care for HER2+ breast cancer, the future of ER+ breast cancer management, and innovations in triple negative breast cancer therapy. Transcript Dr. Allison Zibelli: Hello and welcome to the ASCO Daily News Podcast. I'm Dr. Allison Zibelli, your guest host of the podcast today. I'm an associate professor of medicine and a breast medical oncologist at the Sidney Kimmel Comprehensive Cancer Center at Jefferson Health. There was a substantial amount of exciting breast cancer data presented at the 2025 ASCO Annual Meeting, and I'm delighted to be joined by Dr. Rebecca Shatsky today to discuss some of these key advancements. Dr. Shatsky is an associate professor of medicine at UC San Diego and the head of breast medical oncology at the UC San Diego Health Moores Cancer Center, where she also serves as the director of the Breast Cancer Clinical Trials Program and the Inflammatory and Triple-Negative Breast Cancer Program.  Our full disclosures are available in the transcript of this episode. Dr. Shatsky, it's great to have you on the podcast today. Dr. Rebecca Shatsky: Thanks, Dr. Zibelli. It's wonderful to be here. Dr. Allison Zibelli: So, we're starting with DESTINY-Breast09, which was trastuzumab deruxtecan and pertuzumab versus our more standard regimen of taxane, trastuzumab pertuzumab for first-line treatment of metastatic HER2-positive breast cancer. Could you tell us a little bit about the study? Dr. Rebecca Shatsky: Yeah, absolutely. So, this was a long-awaited study. When T-DXd, or trastuzumab deruxtecan, really hit the market, a lot of these DESTINY-Breast trials were started around the same time. Now, this was a global, randomized, phase 3 study presented by Dr. Sara Tolaney from the Dana-Farber Cancer Institute of Harvard in Boston. It was assessing essentially T-DXd in the first-line setting for metastatic HER2-positive breast cancer in addition to pertuzumab. And that was randomized against our standard-of-care regimen, which was established over a decade ago by the CLEOPATRA trial, and we've all been using that internationally for at least the past 10 years. So, this was a large trial, and it was one-to-one-to-one of patients getting T-DXd plus pertuzumab, T-DXd alone, or THP, which mostly is used as docetaxel and trastuzumab and pertuzumab every three weeks for six cycles. And this was in over 1,000 patients; it was 1,159 patients with metastatic HER2-positive breast cancer. This was a very interesting trial. It was looking at the use of trastuzumab deruxtecan, but patients were started on this treatment for their first-line metastatic HER2-positive breast cancer with no end date to their T-DXd. So, it was, you know, you were started on T-DXd every 3 weeks until progression. Now, CLEOPATRA is a little bit different than that, though, as we know. So, CLEOPATRA has a taxane plus trastuzumab and pertuzumab. But generally, patients drop the taxane after about six to seven cycles because, as we know, you can't be really on a taxane indefinitely. You get pretty substantial neuropathy as well as cytopenias, other things that end up happening. And so, in general, that regimen has sort of a limited time course for its chemotherapy portion, and the patients maintained after the taxane is dropped on their trastuzumab and their pertuzumab, plus or minus endocrine therapy if the investigator so desires. And the primary endpoint of the trial was progression-free survival by blinded, independent central review (BICR) in the intent-to-treat population. And then it had its other endpoints as overall survival, investigator-assessed progression-free survival, objective response rates, and duration of response, and of course, safety. As far as the results of this trial, so, I think that most of us key opinion leaders in breast oncology were expecting that this was going to be a positive trial. And it surely was. I mean, this is a really, really active drug, especially in HER2-positive disease, of course. So, the DESTINY-Breast03 data really established that, that this is a very effective treatment in HER2-positive metastatic breast cancer. And this trial really, again, showed that. So, there were 383 patients that ended up on the trastuzumab plus deruxtecan plus pertuzumab arm, and 387 got THP, the CLEOPATRA regimen. What was really interesting also to note of this before I go on to the results was that 52% of patients on this trial had de novo metastatic disease. And that's pretty unusual for any kind of metastatic breast cancer trial. It kind of shows you, though, just how aggressive this disease is, that a lot of patients, they present with de novo metastatic disease. It's also reflecting the global nature of this trial where maybe the screening efforts are a little bit less than maybe in the United States, and more patients are presenting as later stage because to have a metastatic breast cancer trial in the United States with 52% de novo metastatic disease doesn't usually happen. But regardless, the disease characteristics were pretty well matched between the two groups. 54% of the patients were triple positive, or you could say hormone-positive because whether they were PR positive or ER positive and PR negative doesn't really matter in this disease. And so, the interim data cutoff was February of this year, of 2025. So, the follow-up so far has been about 29 months, so the data is still really immature, only 38% mature for progression-free survival interim analysis. But what we saw is that T-DXd plus pertuzumab, it really improved progression-free survival. It had a hazard ratio that was pretty phenomenal at 0.56 with a confidence interval that was pretty narrow of 0.44 to 0.71. So, very highly statistically significant data here. The progression-free survival was consistent across all subgroups. Overall survival, very much immature at this time, but of course, the trend is towards an overall survival benefit for the T-DXd group. The median durable response with T-DXd plus pertuzumab exceeded 3 years. Now, importantly, though, I want to stress this, is grade 3 or above treatment-emergent adverse events occurred in both subgroups pretty equally. But there were 2 deaths in the T-DXd group due to interstitial lung disease. And there was a 12.1% adjudicated drug-induced interstitial lung disease/pneumonitis event rate in the T-DXd group and only 1%, and it was grade 1-2, in the THP group. So, that's really the caveat of this therapy, is we know that a percentage of patients are going to get interstitial lung disease, and that some may have very serious adverse events from it. So, that's always something I keep in the back of my mind when I treat patients with T-DXd. And so, overall, the conclusions of the trial were pretty much a slam dunk. T-DXd plus pertuzumab, it had a highly statistically significant and clinically meaningful improvement in progression-free survival versus the CLEOPATRA regimen. And that was across all subgroups for first-line metastatic HER2-positive breast cancer here. And so, yeah, the data was pretty impressive. Just to go into the overall response rate, because that's always super important as well, you had 85.1% of patients having a confirmed overall RECIST response rate in the T-DXd plus pertuzumab group and a 78.6 in the CLEOPATRA group. The complete CR rate, complete response was 15.1% in the T-DXd group and 8.5 in the CLEOPATRA regimen. And it was really an effective regimen in this group, of course. Dr. Allison Zibelli: So, the investigators say at the end of their abstract that this is the new standard of care. Would you agree with that statement? Dr. Rebecca Shatsky: Yeah, that was a bold statement to make because I would say in the United States, not necessarily at the moment because the quality of life here, you have to think really hard about. Because one thing that's really important about the DESTINY-Breast09 data is that this was very much an international trial, and in many of the countries where patients enrolled on this, they were not able to access T-DXd off trial. And so, for them, this means T-DXd now or potentially never. And so, that is a really big difference whereas internationally, that may mean standard of care. However, in the US, patients have no issues accessing T-DXd in the second- or third-line settings. And right now, it's the standard of care in the second line in the United States, with all patients basically getting this second-line therapy except for some unique patients where they may be doing a PATINA trial regimen, which we saw at San Antonio Breast Cancer in 2024 of the triple-positive patients getting hormonal therapy plus palbociclib, which had a really great durable response. That was super impressive as well. Or there is the patient that the investigator can pick KADCYLA because the patient really wants to preserve their hair or maybe it's more indolent disease. But the quality of life on T-DXd indefinitely in the first-line setting is a big deal because, again, that CLEOPATRA regimen allows patients to drop their chemotherapy component about five to six months in. And with this, you're on a drug that feels very chemo-heavy indefinitely. And so, I think there's a lot more to investigate as far as what we're going to do with this data in the United States because it's a lot to commit a patient in the first-line metastatic setting. These de novo metastatic patients, some of them may be cured, honestly, on the HER2-targeting regimen. That's something we see these days. Dr. Allison Zibelli: So, very interesting trial. I'm sure we'll be talking about this for a long time.  So, let's move on to SERENA-6, which was, I thought, a very interesting trial. This trial took patients with ER positive, advanced breast cancer after six months on an AI (aromatase inhibitor) and a CDK4/6 inhibitor. They did ctDNA every two to three months, and when they saw an ESR1 mutation emerge, they changed half of the patients to camizestrant plus CDK4/6 and kept the other half on the AI plus CDK4/6. Can you talk about that trial a little bit, please? Dr. Rebecca Shatsky: Yeah, so this was a big trial at ASCO25. This was presented as a Plenary Session. So, this was camizestrant plus a CDK4/6 inhibitor, and it could have been any of the three, so palbo, ribo, or abemaciclib in the first-line metastatic hormone-positive population, and patients were on an AI with that. They were, interestingly, tested by ctDNA at baseline to see if they had an ESR1 mutation. So, that was an interesting feature of this trial. But patients had to have already been on their CDK4/6 inhibitor plus AI for at least 6 months to enroll. And then, as you mentioned, they got ctDNA testing every 2 to 3 months. This was also a phase 3, double-blind, international trial. And I do want to highlight again, international here, because that's important when we're considering some of this data in the U.S. because it influences some of the results. So, this was presented by Dr. Nick Turner of the Royal Marsden in the UK. So, just a little bit of background for our listeners on ESR1 mutations and why they're important. This is the most common, basically, acquired resistance mutation to patients being treated with aromatase inhibitors. We know that treatment with aromatase inhibitors can induce this. It makes a conformational change in the estrogen receptor that makes the estrogen receptor constitutively active, which allows the cell to signal despite the influence of the aromatase inhibitor to decrease the estrogen production so that the ligand binding doesn't matter as much as far as the cell signaling and transcription is concerned. And camizestrant, you know, as an oral SERD, just to explain that a little bit too; these are estrogen receptor degraders. The first-in-class of a selective estrogen receptor degrader to make it to market was fulvestrant. And that's really been our standard-of-care estrogen degrader for the past 25 years, almost 25 years. And so, a lot of us are just looking for some of these oral SERDs to replace that. But regardless, they do tend to work in the ESR1-mutated population. And we know that patients on aromatase inhibitors, the estimates of patients developing an ESR1 mutation, depending on which study you look at, somewhere between 30% to 50% overall, patients will develop this mutation with hormone-positive metastatic breast cancer. There is a small percentage of patients that have these at baseline without even treatment of an aromatase inhibitor. The estimates of that are somewhere between 0.5 and up to 5%, depending on the trial you look at and the population. But regardless, there is a chance someone on their CDK4/6 inhibitor plus AI at 6 months' time course could have had an ESR1 mutation at that time. But anyway, so they got this ctDNA every 2 to 3 months, and once they were found to develop an ESR1 mutation, the patients were then switched to the oral SERD. AstraZeneca's version of the oral SERD is camizestrant, 75 mg daily. And then their type of CDK4/6 inhibitor was maintained, so they didn't switch the brand of their CDK4/6 inhibitor, importantly. And that was looked at then for progression-free survival, but these were patients with measurable disease by RECIST version 1.1. And the data cut off here was November of 2024. This was a big trial, you know, and I think that that's influential here because this was 3,256 patients, and that's a lot of patients. So, they were all eligible. And then 315 patients ended up being randomized to switch to camizestrant upon presence of that ESR1 mutation. So, that was 157 patients. And then the other half, so they were randomized 1:1, they continued on their AI without switching to an oral SERD. That was 158 patients. They were matched pretty well. And so, their baseline characteristics, you know, the two subgroups was good. But this was highly statistically significant data. I'm not going to diminish that in any way. Your hazard ratio was 0.44. Highly statistically significant confidence intervals. And you had a median progression-free survival in those that switched to camizestrant of 16 months, and then the non-switchers was 9.2 months. So, the progression-free survival benefit there was also consistent across the subgroups. And so, you had at 12 months, the PFS rate was 60.7% for the non-treatment group and 33.4% in the treatment group. What's interesting, though, is we don't have overall survival data. This is really immature, only 12% mature as far as overall survival. And again, because this was an international trial and patients in other countries right now do not have the access to oral SERDs that the United States does, the crossover rate, they were not allowed to crossover, and so, a very few patients, when we look at progression-free survival 2 and ultimately overall survival, were able to access an oral SERD in the off-trial here and in the non-treatment group. And so, that's really important as far as we look at these results. Adverse events were pretty minimal. These are very safe drugs, camizestrant and all the other oral SERDs. They have some mild toxicities. Camizestrant is known for something weird, which is called photopsia, which is some flashing lights in the periphery of the eye, but it doesn't seem to have any serious clinical significance that we know of. It has a little bit of bradycardia, but it's otherwise really well tolerated. You know, I hate to say that because that's very subjective, right? I'm not the one taking the drug. But it doesn't have any serious adverse events that would cause discontinuation. And that's really what we saw in the trial. The discontinuation rates were really low. But overall, I mean, this was a positive trial. SERENA-6 showed that switching to camizestrant at the first sign of an ESR1 mutation on CDK4/6 inhibitor plus AI improved progression-free survival. That's all we can really say from it right now. Dr. Allison Zibelli: So, let's move on to ASCENT-04, which was a bit more straightforward. Sacituzumab govitecan plus pembrolizumab versus chemotherapy plus pembrolizumab in PD-L1-positive, triple-negative breast cancer. Could you talk about that study? Dr. Rebecca Shatsky: Yeah, so this was also presented by the lovely Sara Tolaney from Dana-Farber. And this study made me really excited. And maybe that's because I'm a triple-negative breast cancer person. I mean, not to say that I don't treat hundreds of patients with hormone- positive, but our unmet needs in triple negative are huge because this is a disease where you have got to throw your best available therapy at it as soon as you can to improve survival because survival is so poor in this disease. The average survival with metastatic triple-negative breast cancer in the United States is still 13-18 months, and that's terrible. And so, for full disclosure, I did have this trial open at my site. I was one of the site PIs. I'm not the global PI of the study, obviously. So, what this study was was for patients who had had at least a progression-free survival of 6 months after their curative intent therapy or de novo metastatic disease. They were PD-L1 positive as assessed by the Dako 22C3 assay of greater than or equal to a CPS score of 10. So, that's what the KEYNOTE-355 trial was based on as well. So, standard definition of PD-L1 positive in breast cancer here. And basically, these patients were randomized 1:1 to either their sacituzumab govitecan plus pembrolizumab, day 1 they got both therapies, and then day 8 just the saci, as is standard for sacituzumab. And then the other group got the KEYNOTE-355 regimen. So, that is pembrolizumab with – your options are carbogem there, paclitaxel or nab-paclitaxel. And it's up to investigator's decision which upon those they decided. They followed these patients for disease progression or unacceptable toxicity. It was really an impressive trial in my opinion because we know already that this didn't just improve progression-free survival, because survival is so poor in this disease, of course, we know that it improved overall survival. It's trending towards that very much, and I think that's going to be shown immediately. And then the objective response rates were better, which is key in this disease because in the first-line setting, you've got a lot of people who, especially your relapsed TNBC that don't respond to anything. And you lose a ton of patients even in the first-line setting in this disease. And so, this was 222 patients to chemotherapy and pembro and 221 to sacituzumab plus pembro. Median follow-up has only been 14 months, so it's still super early here. Hazard ratio so far of progression-free survival is 0.65, highly statistically significant, narrow confidence intervals. And so, the median duration of response here for the saci group was 16.5 months versus 9.2 months. So, you're getting a 7-month progression-free survival benefit here, which in triple negative is pretty fantastic. I mean, this reminds me of when we saw the ASCENT data originally come out for sacituzumab, and we were all just so happy that we had this tool now that doubled progression-free and overall survival and made such a difference in this really horrible disease where patients do poorly. So, OS is technically immature here, but it's really trending very heavily towards improvement in overall survival. Importantly, the treatment-related adverse events in this, I mean, we know sacituzumab causes neutropenia, people who are experienced with this drug know how to manage it at this point. There wasn't any really unexpected treatment-related adverse events. You get some people with sacituzumab who have diarrhea. It's usually pretty manageable with some Imodium. So, it was cytopenias predominantly in this disease in this population that were highlighted as far as adverse events. But I'm going to be honest, like I was surprised that this wasn't the plenary over the SERENA-6 data because this, in my mind, there we have a practice-changing trial. I will immediately be trying to use this in my PD-L1 population because, to be honest, as a triple-negative breast cancer clinical specialist, when I get a patient with metastatic triple-negative breast cancer who's PD-L1 positive, I think, "Oh, thank God," because we know that part of the disease just does better in general. But now I have something that really could give them a durable response for much longer than I ever thought possible when I started really heavily treating this disease. And so, this was immediately practice-changing for me. Dr. Allison Zibelli: I think that it's pretty clear that this is at least an option, if not the option, for this group of patients. Dr. Rebecca Shatsky: Yeah, the duration of responses here was – it's just really important because, I mean, I do think this will make people live longer. Dr. Allison Zibelli: So, moving on to the final study that we're going to discuss today, neoCARHP (LBA500), which was neoadjuvant taxane plus trastuzumab, pertuzumab, plus or minus carbo(platin) in HER2-positive early breast cancer. I think this is a study a lot of us have been waiting for. What was the design and the results of this trial? Dr. Rebecca Shatsky: I was really excited about this as well because I'm one of those people that was waiting for this. This is a Chinese trial, so that is something to take note of. It wasn't an international trial, but it was a de-escalation trial which had become really popular in HER2-positive therapy because we know that we're overtreating HER2-positive breast cancer in a lot of patients. A lot of patients we're throwing the kitchen sink at it when maybe that is not necessary, and we can really de-escalate and try to personalize therapy a little bit better because these patients tend to do well. So, the standard of care, of course, in HER2-positive curative intent breast cancer with tumors that are greater than 2 cm is to give them the TCHP regimen, which is docetaxel, carboplatin, trastuzumab, and pertuzumab. And that was sort of established by several trials in the NeoSphere trial, and now it's been repeated in a lot of different studies as well. And so, that's really the standard of care that most people in the United States use for HER2-positive curative intent breast cancer. This was a trial to de-escalate the carboplatin, which I was super excited about because many of us who treat this disease a lot think carbo is the least important part of the therapy you're giving there. We don't really know that it's necessary. We've just been doing it for a long time, and we know that it adds a significant amount of toxicity. It causes thrombocytopenia, it causes severe nausea, really bad cytopenias that can be difficult in the last few cycles of this to manage. So, this trial was created. It randomized patients one to one with stage 2 and 3 HER2-positive breast cancer to either get THP, a taxane, pertuzumab, trastuzumab, similar to the what we do in first-line metastatic HER2-positive versus the whole TCHP with a carboplatin AUC of 6, which is what's pretty standard. And it was a non-inferiority trial, so important there. It wasn't to establish superiority of this regimen, which none of us, I think, were looking for it to. And it was a modified intent-to-treat population. And so, all patients got at least one cycle of this to be assessed as a standard for an intent-to-treat trial. And so, they assumed a pCR rate of about 62.8% for both groups. And, of course, it included both HER2-positive triple positives and ER negatives, which are, you know, a bit different diseases, to be honest, but we all kind of categorize them and treat them the same. And so, this trial was powered appropriately to detect a non-inferiority difference. And so, we had about 380 patients treated on both arms, and there was an absolute difference of only 1.8% of those treated with carbo versus those without. Which was fantastic because you really realized that de-escalation here may be something we can really do. And so, the patients who got, of course, the taxane regimen had fewer adverse events. They had way fewer grade 3 and 4 adverse events than the THP group. No treatment-associated deaths occur, which is pretty standard for- this is a pretty safe regimen, but it causes a lot of hospitalizations due to diarrhea, due to cytopenias, and neutropenic fever, of course. And so, I thought that this was something that I could potentially enact, you know, and be practice-changing. It's hard to say that when it's a trial that was only done in China, so it's not necessarily the United States population always. But I think for patients moving forward, especially those with, say, a 2.5 cm tumor, you know, node negative, those, I'd feel pretty comfortable not giving them the carboplatin here. Notes that I want to make about this population is that the majority were stage 2 and not stage 3. They weren't necessarily your inflammatory HER2-positive breast cancer patients. And that the taxane that was utilized in the trial is a little different than what we use in the United States. The patients were allowed to get nab-paclitaxel, which we don't have FDA approval for in the first-line curative intent setting for HER2-positive breast cancer in the United States. So, a lot of them got abraxane, and then they also got paclitaxel. We tend to use docetaxel every 3 weeks in the United States. So, just to point out that difference. We don't really know if that's important or not, but it's just a little bit different to the population we standardly treat. Dr. Allison Zibelli: So, are there patients that you would still give TCHP to? Dr. Rebecca Shatsky: Yeah, great question. I've been asked that a lot in the past like week since ASCO. I'd say in my inflammatory breast cancer patients, that's a group I do tend to sometimes throw the kitchen sink at. Now, I don't actually use AC in those because I know that that was the concern, but I think the TRAIN-2 trial really showed us you don't need to use Adriamycin in HER2-positive disease unless it's like refractory. So, I don't know that I would throw this on my stage 3C or inflammatory breast cancer patients yet because the majority of this were not stage 3. So, in your really highly lymph node positive patients, I'm a little bit hesitant to de-escalate them from the start. This is more of a like, if there's serious toxicity concerns, dropping carbo is absolutely fine here. Dr. Allison Zibelli: All right, great.  Thank you, Dr. Shatsky, for sharing your valuable insights with us on the ASCO Daily News Podcast today. Dr. Rebecca Shatsky: Thanks so much, Dr. Zibelli and ASCO Daily News. I really want to thank you for inviting me to talk about this today. It was really fun, and I hope you find my opinions on some of this valuable. And so, I just want to thank everybody and my listeners as well. Dr. Allison Zibelli: And thank you to our listeners for joining us today. You'll find the links to all the abstracts discussed today in the transcript of this episode. Finally, if you like this podcast and you learn things from it, please take a moment to rate, review, and describe because it helps other people find us wherever you get your podcasts. Thank you again. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers Dr. Allison Zibelli Dr. Rebecca Shatsky @Dr_RShatsky Follow ASCO on social media:  @ASCO on Twitter  @ASCO on Bluesky  ASCO on Facebook  ASCO on LinkedIn   Disclosures: Dr. Allison Zibelli: No relationships to disclose Dr. Rebecca Shatsky: Consulting or Advisory Role: Stemline, Astra Zeneca, Endeavor BioMedicines, Lilly, Novartis, TEMPUS, Guardant Health, Daiichi Sankyo/Astra Zeneca, Pfizer Research Funding (Inst.): OBI Pharma, Astra Zeneca, Greenwich LifeSciences, Briacell, Gilead, OnKure, QuantumLeap Health, Stemline Therapeutics, Regor Therapeutics, Greenwich LifeSciences, Alterome Therapeutics  

Toronto-based nutritionist Leslie Beck heard Monday morning at 8:20 on The Andrew Carter Morning Show. She spoke to Ken Connors about the possible inflammatory properties of dairy.

The Utah Senator was confronted by fellow Senator Tina Smith after his post about the shooting in Minnesota. What happened next? Listen to the Senator and Tom Hauser on The WCCO Morning News. Photo courtesy of Kayla Bartkowski/Getty Images

The Utah Senator was confronted by fellow Senator Tina Smith after his post about the shooting in Minnesota. What happened next? Listen to the Senator and Tom Hauser on The WCCO Morning News. Photo courtesy of Kayla Bartkowski/Getty Images

Dr. Uma Naidoo founded and directs the first hospital-based Nutritional Psychiatry Service in the United States. She is the Director of Nutritional and Lifestyle Psychiatry at Massachusetts General Hospital (MGH) & Director of Nutritional Psychiatry at MGH Academy while serving on the faculty at Harvard Medical School. She was considered Harvard's Mood Food Expert and has been featured in the Wall Street Journal. Dr. Naidoo is also the national bestselling author of This Is Your Brain on Food and her newest book, Calm Your Mind with Food is available now.  In this fascinating rerun episode (first aired in 2020), Erin and Dr. Naidoo discuss her 2020 book, This Is Your Brain On Food. Key Topics: * Dr. Naidoo's journey as a psychiatrist and professional chef * How what we eat affects our brain * The origin of the gut/brain connection * The rise of mental health concerns * Food to avoid for mental well-being * Inflammatory foods * Orthorexia and food obsession * How to add more diversity in your diet * The impact of caffeine and alcohol on mental health Join Erin's monthly mailing list to get health tips and fresh meal plans and recipes every month: https://mailchi.mp/adde1b3a4af3/monthlysparksignup Preorder Erin's new book, Live Beyond Your Label, at erinbkerry.com/upcomingbook/

Dr. David Furman and Dr. Buck Joffrey discuss the complexities of immune aging, the role of inflammation in age-related diseases, and how artificial intelligence is being utilized to enhance research in this field. He introduces the concept of the inflammatory age clock, which measures biological aging through immune system signals, and explores potential therapeutic interventions, including nutraceuticals and therapeutic plasma exchange. The discussion also touches on the future of aging research, emphasizing personalized approaches and the democratization of diagnostics. Learn more about Dr. David Furman: https://www.buckinstitute.org/lab/furman-lab/

In this episode of the RCP Medicine podcast, Professor Ailsa Hart and Dr Eathar Shakweh discuss how to approach managing Inflammatory Bowel Disease (IBD) in the acute medical setting. This is the first episode of a 2-part series, with a focus on ulcerative colitis.  IBD is a common condition, affecting 1 in 123 people in the UK. The 2024 State of the IBD Care in the UK report highlighted the urgent need to shorten time to diagnosis and initiate early treatment to minimise the risk of IBD-related complications. Acute and general medicine physicians have an important role to play in diagnosing and managing IBD. This podcast will equip medics at all stages of training with the necessary knowledge to approach this heterogenous and complex condition. Professor Hart is Director of IBD Research at St Mark's Hospital, London, United Kingdom and a world-leading expert in IBD. Eathar is an IBD Clinical Research Fellow at St Mark's and Imperial, with a special interest in perianal fistulising Crohn's disease. Crohn's & Colitis UK (CCUK) Websitehttps://crohnsandcolitis.org.uk/This is a valuable resource for patients and healthcare professionals alike, containing a wealth of information on IBD investigation and management.British Society of Gastroenterology (BSG) guidelines on Inflammatory Bowel Disease (IBD) - 2019Lamb, Christopher Andrew et al. “British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.” Gut vol. 68,Suppl 3 (2019): s1-s106. doi:10.1136/gutjnl-2019-318484https://pubmed.ncbi.nlm.nih.gov/31562236/For interested listeners, these are the national guidelines for IBD diagnosis and management. Please note, the new guidelines for 2025 are pending release.RCP LinksEducation and learning | RCP Events | RCP Membership | RCP Improving care | RCP Policy and campaigns | RCP CreditsMusic by bensound.com

Jane Kirtley, Silha Professor of Media Ethics and Law at the University of Minnesota, joins John Williams to talk about ABC News firing correspondent Terry Moran after he criticized Stephen Miller and President Trump on social media. Jane also breaks down The Pew Research Center news media tracker on how Americans use and trust 30 media […]

Jane Kirtley, Silha Professor of Media Ethics and Law at the University of Minnesota, joins John Williams to talk about ABC News firing correspondent Terry Moran after he criticized Stephen Miller and President Trump on social media. Jane also breaks down The Pew Research Center news media tracker on how Americans use and trust 30 media […]

Send us a textOn this week's WTR Small-Cap Spotlight, we speak with Apimeds CEO Erik Emerson about the newly NYSE listed company and the development of Apitox, a purified honeybee venom, for knee osteoarthritis and multiple sclerosis. We discuss the therapeutic properties of bee venom and the clinical/regulatory plans to bring Apitox to the US market. Listen to learn more about Apimeds and its novel approach to treat inflammatory pain.

Jane Kirtley, Silha Professor of Media Ethics and Law at the University of Minnesota, joins John Williams to talk about ABC News firing correspondent Terry Moran after he criticized Stephen Miller and President Trump on social media. Jane also breaks down The Pew Research Center news media tracker on how Americans use and trust 30 media […]

Kia ora,Welcome to Monday's Economy Watch where we follow the economic events and trends that affect Aotearoa/New Zealand.I'm David Chaston and this is the international edition from Interest.co.nz.And today we lead with news that despite the Trump-generated spectacle of intimidation and violence in Los Angeles against immigrant communities, the economic news has been contained.This coming week is not a big one for local data releases, but in Australia we will get updated surveys of both consumer (Westpac/MI), and business (NAB) sentiment surveys. Not a lot of change is expected in either.There will be a June update of American consumer sentiment from the widely watched University of Michigan. And we will get CPI updates for May from both the US (expect a small rise to 2.5% (and China (expect slightly deeper deflation at -.2%). India will also release May CPI data (expect little change).The Chinese will also release export and import data. Japan will update its machine tool order data. And Germany will release some wholesale price data too.Over the weekend, and in something of a relief, the US May non-farm payrolls growth came in at +139,000, little different to the expected +130,000 and only a minor retreat from the +147,000 growth in April. But that is a bit below the average for 2024 and well below the average for 2023, and the lowest expansion for a May since 2020. In data not seasonally adjusted, it was the lowest since 2016. The US labour market seems to be plateauing after a rather strong recovery in the prior four years.Average US weekly earnings rose +3.9% in May from the same month a year ago, similar to earlier 2025 months and the same as the average for a May over the past ten years. The jobless rate was unchanged at 4.2%.But hiring freezes and production cutbacks seem to be the themes coming out of corporate America. The landscape for reshoring isn't good, apparently.And the data is becoming clearer that foreigners are avoiding the US as a travel destination, and not just Canadians, with anti-American sentiment on the rise in Europe too. Companies like Airbnb, Booking.com and Expedia all said that their financial results will be weaker than expected because of the softening demand.Total US consumer credit rose by +US$18 bln in April or +4.3%, up from a +$10 bln increase in March and better than expected. So this expansion, while modest, is back to a 'normal' pace. Revolving credit (credit cards) increased at an annual rate of +7%, while nonrevolving credit (car loans and similar) rose at a letter 3.3% rate.There was May Canadian labour market data out over the weekend too. Somewhat surprisingly, that delivered an expansion of +8,800 jobs when a -15,000 reduction was anticipated. Even better, +57,700 new full-time jobs were added in May balanced by a reduction of -48,800 part-time jobs. So, overall a rather surprising net gain.However, their jobless rate rose to 7%, the first time it has hit that level since 2016 (apart from the pandemic), so that probably raises the chance of a rate cut at their next review at the end of July.In Japan, the level of central bank bond buying tapering continues to raise concerns and undermine demand by other potential investors. It is also raising questions about the value of the yen. There is elevated debate about the right level from here and the central bank may have to slow its tapering operation. The void their tapering is leaving is not being filled by the private sector. And that could seriously twist Japanese interest rates.Late on Friday, the Indian central bank cut its policy rate again, with an outsized -50 bps cut to 5.5% when a -25 bps trim was expected. That makes it a full -100 bps reduction since February. They say the outsized move was required by the combination of fast- easing inflation and ongoing uncertainty surrounding global trade tensions.The Russian central bank also surprised with a rate cut when one wasn't expected. It cut -100 bps to 20% under Kremlin pressure, and claiming that "inflation is under control".EU retail sales for April came in surprisingly strong. They report these on a volume basis and were +2.8% higher than in April 2024. Only a +1.4% expansion was expected, and the March expansion was +1.9%. So a great result for them. Most other countries are not getting inflation-adjusted retail growth anything like this.Today is a public holiday in Australia, so our markets will be quiet.Meanwhile, both sides seem to be gearing up for trade talks between China and the US - in London.The UST 10yr yield is now at 4.51%, and unchanged from Saturday, up +9 bps for the week. The price of gold will start today at US$3,308/oz, and down -US$10 from Saturday. That is up +US$24 from US$3294/oz a week ago.American oil prices are holding at just on US$64.50/bbl while the international Brent price is still the same at just on US$66.50/bbl.The Kiwi dollar is now at 60.2 USc, and unchanged from Saturday at this time. Against the Aussie we are also unchanged at 92.7 AUc. Against the euro we are still at 52.8 euro cents. That all means our TWI-5 starts today at just on 68.2 and unchanged from Saturday.The bitcoin price starts today at US$106,270 and up +1.5% from Saturday. Volatility over the past 24 hours has been low at just under +/-0.6%.You can get more news affecting the economy in New Zealand from interest.co.nz.

Have you heard that seed oils are inflammatory and bad for you? What does science say about this? Does canola oil and linoleic acid really cause inflammation and lead to heart disease? These questions and more are tackled in this episode with one of the top 2% of scientists in the world Dr. Bill Harris who has been researching fatty acids for over 40 years We cover: Why are we so scared of seed oils and are they really damaging our bodies? What about the oxidation that comes with processing, pressuring and high heat? Do we need to replace seed and vegetable oils with something else? Should we be lowering our omega 6s and increasing omega 3s? Should we be testing our omega ratio? How should we be changing our diets to have better health outcomes? Why do we see so much conflicting research? Is it better to eat saturated fats like butter and coconut oil? What about the oxidation in omega 3 supplements Toxins, heavy metals and so much more   Dr. Bill Harris has been a leading researcher in the omega-3 fatty acid field for 40 years. He has over 360 scientific papers on fatty acids and health, the vast majority on omega-3. He has been on the faculty of three medical schools (Universities of Kansas, Missouri (at Kansas City), and South Dakota), and has received 5 NIH grants to study omega-3. He was the co-author on three AHA statements on fatty acids and heart health. As the co-inventor of the Omega-3 Index (and other omega-3 blood tests) and founder of OmegaQuant Analytics, Dr. Harris has been ranked among the top 2% of scientists worldwide based on the impact of his research.   omegaquant.com (OmegaQuant) and fareinst.org (Fatty Acid Research Institute) HACKMYAGE10 for 10% off your entire order @OmegaQuant.com (cannot be combined with other offers and expires July 31, 2025).   Contact Dr. Bill Harris: Facebook: @Omega3Index  Instagram: @OmegaQuant  YouTube: @OmegaQuantLab  LinkedIn: @OmegaQuant-Analytics  X: @OmegaQuant  Newsletter signup: https://omegaquant.activehosted.com/f/7   Give thanks to our sponsors: Qualia senolytics and brain supplements. 15% off with code ZORA here. Try Vitali skincare. 20% off with code ZORA here https://vitaliskincare.com Get Primeadine spermidine by Oxford Healthspan. 15% discount with code ZORA ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠here⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Get Mitopure Urolithin A by Timeline. 10% discount with code ZORA at https://timeline.com/zora Try Suji to improve muscle 10% off with code ZORA at TrySuji.com https://trysuji.com Get Magnesium Breakthrough by Bioptimizers. 10% discount with code HACKMYAGE at https://bioptimizers.com/hackmyage Try OneSkin skincare with code ZORA for 15% off https://shareasale.com/r.cfm?b=2685556&u=4476154&m=102446&urllink=&afftrack= Join ⁠⁠⁠Biohacking Menopause⁠⁠⁠ before July 1, 2025 to win free Vitali Skincare! 20% off with code ZORA at VitaliSkincare.com   Join the Hack My Age community on: Facebook Page: ⁠⁠⁠⁠⁠@⁠Hack My Age⁠     https://www.facebook.com/HackMyAge Facebook Group: ⁠⁠⁠⁠⁠⁠@⁠Biohacking Menopause⁠⁠⁠⁠⁠⁠ ⁠  Private Women's Only Support Group: https://hackmyage.com/biohacking-menopause-membership/ Instagram: ⁠⁠⁠⁠⁠@⁠HackMyAge⁠    Website: ⁠⁠⁠⁠⁠⁠HackMyAge.com⁠   

Barry Quart, CEO of Connect Biopharma, is developing the next generation of monoclonal antibodies targeting inflammatory respiratory diseases such as COPD and asthma. Administered subcutaneously, their lead program targets IL-4 and has demonstrated the ability to rapidly improve airway function and reduce the incidence of acute exacerbations in these patients. Current treatments rely on steroids and bronchodilators, which do not address the underlying inflammatory causes, an area that has largely been under-addressed by other biologic developers. Barry explains, "Connect has been dedicated for quite a few years to designing next-generation monoclonal antibodies targeting inflammatory diseases. I joined the company last year and really kind of turned the ship towards a sole focus on our lead program, which is rademikibart, a second-generation Dupixent, a monoclonal antibody targeting IL-4, a really important target for certain inflammatory diseases." "IL-4 can be used as a monoclonal antibody targeting IL-4 for diseases such as atopic dermatitis, asthma, and COPD, as well as several other conditions. We're focused on asthma and COPD. So, inflammatory respiratory disease, because our product has some unique characteristics that are going to allow us to focus on an area that's really been completely ignored by other developers of biologics in the respiratory space, and specifically on patients having acute exacerbations."  #ConnectBiopharma #MonoclonalAntibody #IL4 #COPD #Asthma #AtopicDermatitis #InflammatoryDiseases #RespiratoryDiseases connectbiopharm.com Download the transcript here

Barry Quart, CEO of Connect Biopharma, is developing the next generation of monoclonal antibodies targeting inflammatory respiratory diseases such as COPD and asthma. Administered subcutaneously, their lead program targets IL-4 and has demonstrated the ability to rapidly improve airway function and reduce the incidence of acute exacerbations in these patients. Current treatments rely on steroids and bronchodilators, which do not address the underlying inflammatory causes, an area that has largely been under-addressed by other biologic developers. Barry explains, "Connect has been dedicated for quite a few years to designing next-generation monoclonal antibodies targeting inflammatory diseases. I joined the company last year and really kind of turned the ship towards a sole focus on our lead program, which is rademikibart, a second-generation Dupixent, a monoclonal antibody targeting IL-4, a really important target for certain inflammatory diseases." "IL-4 can be used as a monoclonal antibody targeting IL-4 for diseases such as atopic dermatitis, asthma, and COPD, as well as several other conditions. We're focused on asthma and COPD. So, inflammatory respiratory disease, because our product has some unique characteristics that are going to allow us to focus on an area that's really been completely ignored by other developers of biologics in the respiratory space, and specifically on patients having acute exacerbations."  #ConnectBiopharma #MonoclonalAntibody #IL4 #COPD #Asthma #AtopicDermatitis #InflammatoryDiseases #RespiratoryDiseases connectbiopharm.com Listen to the podcast here

Chronic sinusitis might be doing more than just clogging your nose–it could be clouding your brain. In this episode of Backtable ENT, Dr. Aria Jafari, an assistant professor at the University of Washington and co-director of the Neuroendocrinology Advanced Sinus and Skull-base Surgery Fellowship, discusses the connection between sinusitis and cognitive dysfunction with hosts Dr. Gopi Shah and Dr. Ashley Agan. --- SYNPOSIS Dr. Jafari shares how his interest in this field developed and details his research on the relationship between chronic rhinosinusitis (CRS) and brain function. The conversation highlights the comprehensive impact of sinus inflammation on overall health, emphasizing the importance of viewing CRS as a whole-body condition. They also discuss patient experiences, the methodologies used to assess cognitive dysfunction, potential treatments, and what's next in the research frontier.---TIMESTAMPS00:00 - Introduction 06:18 - The Impact of CRS on Quality of Life14:02 - Understanding Brain Fog and Cognitive Dysfunction24:29 - Pathophysiology and Theories of Cognitive Dysfunction27:44 - Chronic Inflammation and Cognitive Effects28:59 - Impact of Biologics on Cognitive Function31:28 - Risk Factors for Cognitive Dysfunction35:02 - Olfactory Symptoms 37:13 - Future Research and Treatment Approaches45:31 - Conclusion and Final Thoughts --- RESOURCES Dr. Aria Jafari https://www.uwmedicine.org/bios/aria-jafari

About Ric Kealoha, MD:   Dr. Ric Kealoha is an American Physician specializing in functional and longevity medicine, with active medical licenses in four countries. As a forward-thinking leader in the holistic health revolution, Dr. Kealoha combines cutting-edge research, data-driven protocols, and patient-centered care to redefine how healthcare professionals and entrepreneurs approach wellness, performance, and disease prevention. With extensive experience treating high-achieving professionals, executives, and entrepreneurs, Dr. Kealoha has built a reputation for precision-driven, root-cause personalized medicine that optimizes human health beyond traditional allopathic clinical models. He is deeply committed to empowering people, healthcare professionals, and doctors by bridging the gap between functional integrative medicine, alternative therapies, and AI-powered health solutions. As one of the 4 visionaries behind MET@BOLICS+, Dr. Kealoha is spearheading an AI-driven revolution and transformation in personalized healthcare and functional medicine, leveraging technology to make science-backed holistic wellness accessible to millions worldwide. His mission is to disrupt outdated medical paradigms, combat misinformation, and create scalable, high-impact health solutions that drive both better patient outcomes and long-term investor value. With a track record of innovation and execution, Dr. Kealoha is positioning MET@BOLICS + as the premier AI-powered healthcare and wellness platform, merging profitability with purpose in a rapidly growing 200B   What We Discuss In This Episode: Issues with Traditional Hormone Testing/Treatment Basic blood tests often miss underlying issues (e.g. thyroid problems) Doctors frequently dismiss symptoms or use one-size-fits-all approaches Hormone replacement often uses synthetic/animal-derived hormones with side effects Lack of education on perimenopause/menopause for many doctors (only ~1 hour in med school) Advanced Hormone Testing and Analysis Comprehensive urine tests examine entire hormone system Detects xenoestrogens from plastics, pesticides, etc. linked to cancer risk Assesses body's ability to eliminate toxic forms of hormones Examines stress hormones like cortisol and their impact Key Factors Impacting Hormonal Health Environmental toxins (cosmetics, cleaners, plastics, etc.) Chronic stress and poor sleep Inflammatory diet (esp. fast food, high carb) Gut health issues ("leaky gut") Excess body fat producing estrogen Psychological/emotional factors Natural Approaches to Hormone Balance Detoxification via supplements (broccoli sprouts, DIM, glutathione, chlorella) Intermittent fasting (tailored for women's cycles) Ketogenic diet to reduce inflammation Increased water intake (3-5L daily, filtered) Stress reduction and mindset shifts Bioidentical hormones if needed Broader Health System Issues Distrust in medical/government institutions growing Many doctors resistant to new research/approaches Food industry practices contributing to obesity epidemic Need for patient and practitioner education on functional approaches   Connect With Dr. Ric Kealoha: Website: https://www.advancedwaysinhealing.com LinkedIn: https://www.linkedin.com/in/ric-kealoha-md-bsc-b6328417b/ Connect with Lynne: If you're looking for a community of like-minded women on a journey - just like you are - to improved health and wellness, overall balance, and increased confidence, check out Lynne's private community in The Energized Healthy Women's Club. It's a supportive and collaborative community where the women in this group share tips and solutions for a healthy and holistic lifestyle. (Discussions include things like weight management, eliminating belly bloat, balancing hormones, wrangling sugar gremlins,  overcoming fatigue, recipes, strategies, perimenopause & menopause, and much more ... so women can feel energized, healthy, and lighter, with a new sense of purpose. Website:  https://holistic-healthandwellness.com Facebook: https://www.facebook.com/holistichealthandwellnessllc The Energized Healthy Women's Club:  https://www.facebook.com/groups/energized.healthy.women Instagram: https://www.instagram.com/lynnewadsworth LinkedIn:  https://www.linkedin.com/in/lynnewadsworth   Free Resources from Lynne Wadsworth: ✨ Ready to Thrive in Midlife? Let's Make It Happen!

Send us a textDr. Michael Bernhardt, a dermatologist and clinical researcher, joins Dr. Erich Schramm to discuss the revolutionary advancements in psoriasis treatment over the past two decades. The doctors discuss how psoriasis is an inflammatory disease more than an autoimmune disease. They discuss what inflammation is, the inflammation pathway in the body, and how different medications can help suppress the body's out-of-control inflammatory response. They go over the history of psoriasis medications, which ones may be appropriate for different severities of the disease, and what's on the cutting edge of psoriasis treatment.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Skin of Color Issues - with Dr. Tia Paul! -Anterior cervical hypertrichosis -A new vascular anomaly: SeCVAUS -Can you just observe SCCis? -Early inflammatory morphe can mimic port-wine stains -Learn more about Dr. Paul at balancedskin.com/ or on Instagram/Tiktok @dr.tiapaul!Join Luke's CME experience on Jak inhibitors! ⁠rushu.gathered.com/invite/ELe31Enb69⁠Register for the U of U Practical Derm course!⁠medicine.utah.edu/dermatology/educ…ities/practical⁠Learn more about the U of U Dermatology ECHO model!⁠physicians.utah.edu/echo/dermatology-primarycare⁠Want to donate to the cause? Do so here!
Donate to the podcast: ⁠uofuhealth.org/dermasphere⁠
Check out our video content on YouTube:
⁠www.youtube.com/@dermaspherepodcast⁠
and VuMedi!: ⁠www.vumedi.com/channel/dermasphere/⁠
The University of Utah's Dermatology
ECHO: ⁠⁠physicians.utah.edu/echo/dermatology-primarycare⁠ -
⁠ Connect with us!
- Web: ⁠⁠dermaspherepodcast.com/⁠⁠ - Twitter: @⁠DermaspherePC⁠
- Instagram: dermaspherepodcast
- Facebook: ⁠www.facebook.com/DermaspherePodcast/⁠
- Check out Luke and Michelle's other podcast,
SkinCast! ⁠⁠healthcare.utah.edu/dermatology/skincast/⁠⁠ Luke and Michelle report no significant conflicts of interest… BUT check out our
friends at:
- ⁠Kikoxp.com ⁠(a social platform for doctors to share knowledge)
- ⁠⁠www.levelex.com/games/top-derm⁠⁠ (A free dermatology game to learn
more dermatology!

On The Other Side of Midnight, Dominic starts the show talking about the killing of two Israeli embassy workers outside the Capital Jewish Museum. Learn more about your ad choices. Visit megaphone.fm/adchoices

Does this sound familiar?   Fatigue Brain fog Skin issues Joint pain   Symptoms like these are not random and they could be a sign of an underlying reaction to certain foods.     These sensitivities aren't always obvious and often go undetected, but with the right tools and a short elimination strategy, you can begin to identify your personal triggers and dramatically improve how you feel each day.     Join me on today's Cabral Concept 3392 as I go over the 5 most common inflammatory food sensitivities we see in our practice and what you can do to uncover whether they're affecting your health.   Enjoy the show, and let me know your thoughts! - - - For Everything Mentioned In Today's Show: StephenCabral.com/3392 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!  

We've compiled the top diets, treatments, and lifestyle tips to help you heal leaky gut. This guide is based on research as well as our experience successfully treating patients in our clinic. Watch now! We can help you heal your gut! Learn more about our virtual clinic:  https://drruscio.com/virtual-clinic/  

Seed oils have recently become a hotly debated topic in nutrition, fueled by sensational claims on social media. In this episode, the central theme is examining whether seed oils are truly harmful or if they've been unjustly demonized. The discussion tackles prevalent claims – that seed oils drive inflammation, oxidation, and chronic disease – and compares them against the current scientific evidence. This is highly relevant to nutrition science and clinical practice today, as many patients and practitioners are encountering conflicting information about vegetable oils. By exploring the origins of seed oils, their biochemical effects, health outcome data, and the misinformation ecosystem, the episode aims to clarify how omega-6 rich seed oils fit into a healthy diet and what evidence-based guidelines say. Timestamps 01:00 Understanding terms: PUFA, Linoleic Acid, Omega-6 05:20 Do seed oils cause inflammation? 12:44 Omega-3 and omega-6 16:43 Inflammatory markers and linoleic acid 19:22 Oxidation and cooking oils 26:25 Refining processes and health concerns 30:32 Health outcomes and polyunsaturated fats 35:18 Evidence cited by anti-seed oil proponents 43:48 Conclusions Related Resources Join the Sigma email newsletter for free Subscribe to Sigma Nutrition Premium Enroll in the next cohort of our Applied Nutrition Literacy course Sigma Statement: Seed Oils on Trial: Is the Panic Justified? Related podcast episodes: 502: Sydney Diet-Heart Study – Is Linoleic Acid Causing Heart Disease? 504: Vegetable Oil vs. Saturated Fat – Analysis of the LA Veterans Study 505: Oslo Diet-Heart Study: Cholesterol-lowering Diets & Cardiovascular Events 329: Diet & Inflammation

Story at-a-glance Women with chronic migraines and body-wide pain were far more likely to have poor oral health, with over half falling into the lowest oral health categories in a new study Specific oral bacteria, including Mycoplasma salivarium and Gardnerella vaginalis, were significantly more common in women who reported frequent migraines and widespread pain Harmful oral microbes don't stay in your mouth; once gum tissue is inflamed, these bacteria enter your bloodstream, disrupt the immune system, and trigger systemic pain A less diverse oral microbiome was found in women with migraines and gut pain, making it easier for pain-triggering bacteria to dominate and inflame nerve pathways Inflammatory chemicals produced by oral bacteria — like calcitonin gene-related peptide (CGRP) and vascular endothelial growth factor (VEGF) — are directly involved in migraine and fibromyalgia, showing how poor oral hygiene can set off whole-body pain responses

Host: Danielle O'Laughlin, PA-C, MS and Jenna Wygant, APRN, CNP, DNP Guest: Danielle O'Laughlin, PA-C, MS In this episode, along with host/guest Danielle O'Laughlin, PA-C, MS, we will discuss benign, inflammatory breast conditions. We will cover how to differentiate between common issues such as mastitis, breast abscess, fat necrosis, galactorrhea, and gynecomastia. We'll walk through the key signs and symptoms to watch for and explore how each condition is diagnosed and treated. This episode offers valuable insights into these non-cancerous yet very important conditions. By the end of this podcasts, listeners will be able to: Differentiate the benign, inflammatory breast conditions including mastitis, breast abscess, fat necrosis, galactorrhea, and gynecomastia. Recognize the signs and symptoms for benign, inflammatory breast conditions. Summarize the diagnosis and treatment options for benign, inflammatory breast conditions. Learn more about this series: Mayo Clinic Talks: Obstetric and Gynecologic Health | Mayo Clinic School of Continuous Professional Development Connect and listen with Mayo Clinic Podcasts | Mayo Clinic School of Continuous Professional Development

Inflammatory markers can double within six hours of eating a pro-inflammatory meal. Which foods are the worst, and which ones reduce inflammation? What does an anti-inflammatory diet look like?

Inflammatory bowel diseases like ulcerative colitis remain among the most difficult chronic conditions to manage — but new science at the intersection of microbiome research and biotechnology may offer hope.In this episode of The Mind-Gut Conversation, I sit down with Dr. Deanna Gibson, microbiome researcher and cofounder of Melius Microbiomics, to explore how genetically engineered microbial medicines could transform the future of IBD treatment — and what it will take for patients and the medical community to embrace them.In this conversation, we explore:· How Dr. Gibson's research led to the development of BioPersist™ and BioColonize™ for IBD.· Why new microbiome-targeted therapies are urgently needed — especially for younger patients in whom ulcerative colitis is on the rise.· What makes BioPersist™ different from traditional probiotics and current IBD treatments.· How genetically engineered microbial medicines (GEMMs) represent a new generation of gut therapies.· Early research findings that support BioPersist™ as a promising treatment for ulcerative colitis.· Challenges in gaining public trust for novel biotech therapies amid growing skepticism.· Exciting new discoveries in microbiome science — and the future potential for live biotherapeutics beyond IBD.If you're curious about the exciting direction where gut health research is headed — and how the microbiome may change the way we treat chronic disease — this episode is for you.Tune in and join the conversation!Disclaimer: Dr. Mayer is the Chief Medical Officer of Melius Microbiomics and has been involved in the commercial development of Genetically Engineered Microbial Medicines (GEMMs).

Inflammatory bowel diseases like ulcerative colitis remain among the most difficult chronic conditions to manage — but new science at the intersection of microbiome research and biotechnology may offer hope.In this episode of The Mind-Gut Conversation, I sit down with Dr. Deanna Gibson, microbiome researcher and cofounder of Melius Microbiomics, to explore how genetically engineered microbial medicines could transform the future of IBD treatment — and what it will take for patients and the medical community to embrace them.In this conversation, we explore:· How Dr. Gibson's research led to the development of BioPersist™ and BioColonize™ for IBD.· Why new microbiome-targeted therapies are urgently needed — especially for younger patients in whom ulcerative colitis is on the rise.· What makes BioPersist™ different from traditional probiotics and current IBD treatments.· How genetically engineered microbial medicines (GEMMs) represent a new generation of gut therapies.· Early research findings that support BioPersist™ as a promising treatment for ulcerative colitis.· Challenges in gaining public trust for novel biotech therapies amid growing skepticism.· Exciting new discoveries in microbiome science — and the future potential for live biotherapeutics beyond IBD.If you're curious about the exciting direction where gut health research is headed — and how the microbiome may change the way we treat chronic disease — this episode is for you.Tune in and join the conversation!Disclaimer: Dr. Mayer is the Chief Medical Officer of Melius Microbiomics and has been involved in the commercial development of Genetically Engineered Microbial Medicines (GEMMs).

Have you ever wondered why endometriosis and migraines seem to go hand-in-hand? It's not just a coincidence. In this episode, we explore the hidden hormonal and inflammatory links that bind these two chronic conditions — and what that means for your healing journey.What you'll learn:How endometriosis and migraines are connected through shared hormonal imbalances and inflammatory pathways.The latest research shows the surprising genetic overlap and co-morbidity rates between these two conditions.Why treating symptoms separately often fails — and how Eastern medicine approaches healing at the root cause level.If you've been struggling with migraines, hormonal issues, and mysterious chronic pain, this episode will open your eyes to a more holistic and empowering way to understand and heal your body.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Association of Intramyocardial Hemorrhage With Inflammatory Biomarkers in Patients With ST-Segment Elevation Myocardial Infarction.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Chronic Inflammatory-Related Disease and Cardiovascular Disease in MESA.

Story at-a-glance Ginger has a long history of soothing digestive issues and modern research confirms its ability to reduce gut inflammation and support intestinal healing Inflammatory bowel disease (IBD) increases the risk of serious health issues.IBDs like Crohn's disease and ulcerative colitis cause diarrhea, abdominal pain, and fatigue, increasing the risk of malnutrition, intestinal damage, and colorectal cancer if left untreated A recent study found that furanodienone (FDN) in ginger activates the pregnane X receptor (PXR), which reduces gut inflammation and oxidative stress. It also strengthens the intestinal barrier to prevent harmful bacteria from entering the bloodstream Early use of ginger compounds leads to better outcomes, with reduced symptom severity and faster recovery in gut inflammation, especially when started at the first signs of digestive issues Another study found that gingerols and shogaols suppress immune overactivity, lowering IL-1β and TNF-α while blocking key inflammatory pathways that worsen chronic gut conditions

Today, along with my expert guest, I'll be tackling inflammation, anti-inflammatory foods, and the role of inflammation in our fat loss progress (or lack thereof). CONNECT with Lindsay Cotter at www.cottercrunch.com. Here's the discount link for the anti-inflammatory 21-day meal plan and diet guide, which is valid through the year. For more detailed answers from the podcast interview, here are Lindsay's notes. ENROLL in my next FASTer Way 6-week online class at https://www.fasterwaycoach.com/AMYBRYAN CONNECT with Amy Bryan any of the following ways:  SCHEDULE a discovery call, VOICE MESSAGE me, JOIN my free Facebook community group, and DOWNLOAD my latest freebies at www.linktr.ee/amybryanfasterway EMAIL me at amy@fatlossschool.net

Dr. Scott Stoll presents a transformative program designed to improve your health in just 40 days. Learn about the powerful lifestyle changes that can lead to lifelong wellness and vitality. Start your journey to better health today! #LifetimeHealth #WellnessJourney #HealthyLiving

Rewiring Your Vagus Nerve: A Functional ApproachWhile vagus nerve exercises like cold plunges and humming are popular, this episode explores a deeper functional perspective. What if underlying factors like mineral imbalances, gut issues, mold exposure, or structural misalignments are blocking your vagal function?The Mineral ConnectionYour vagus nerve functions as your body's electrical system, with minerals as crucial conductors. Hair Tissue Mineral Analysis reveals important patterns:- Calcium/Magnesium Ratio: Excessive calcium dominance keeps you stuck in "fight or flight"- Calcium/Phosphorus Ratio: Ideally balanced at 2.3:1 for optimal function- Potassium Levels: Low levels signal insufficient nerve energy- Heavy Metal Burden: Toxic metals hijack nerve function by stealing mineral binding sites"Your vagus nerve is your digestive system's power cord. Mineral imbalances create short circuits!"The Gut-Vagus ConnectionYour gut contains the second largest neural system after the brain. Comprehensive stool testing can identify issues affecting vagal function:- Low microbial diversity correlates with reduced vagal tone- Deficiencies in butyrate-producers deprive the nerve of energy- Dysbiosis creates inflammation that dampens signalingThis creates a feedback loop: poor vagal tone worsens digestive function, increasing dysbiosis, further impairing vagal tone.Mold ExposureMold illness disrupts vagus nerve function through:- Direct neurotoxicity to vagal nuclei- Mitochondrial damage impairing energy production- Inflammatory cascades that dampen vagal toneMany experience treatment resistance because underlying mycotoxin burden continues suppressing function.Structural ConsiderationsThe vagus nerve can physically get "pinched" due to:- Cranial misalignments- Neck tension- Rib cage restrictions- Abdominal compressionThis explains why bodywork sometimes dramatically improves digestion when supplements haven't helped.Practical Support StrategiesWhile addressing root causes, try:1. Singing: Creates vibrations that stimulate the vagus2. Essential Oils: Applied diluted behind the ears3. Digestive Bitters: Trigger vagal firing4. Omega-3 Fatty Acids: Provide building blocks for nerve structureThe Holistic ApproachRather than isolated "hacks," assess your unique terrain. When we restore harmony to the entire ecosystem, vagal tone naturally improves, with benefits cascading throughout your physiology.Looking for deeper support? Visit the "Work With Me" page on my website to learn about my approach to mineral balancing and microbiome optimization – two key pillars that profoundly affect vagus nerve function and overall health. Mineral Foundations Course HERE Learn more about how you can I can work together HERE Book an initial health session HERE Join my newsletter HERE If you are interested in becoming a client and have questions, reach out by emailing me: connect@lydiajoy.me Find me on Instagram : @ Lydiajoy.me OR @ holisticmineralbalancing

See all the Healthcasts at https://www.biobalancehealth.com/healthcast-blog Do you ache all over? Are you weaker every year? Shorter and more bent over?   Are your clothes hanging off your shoulders? Do you walk slower and hold on to things as you walk? If you notice these signs in yourself or someone you love it means you, or they are becoming frail. As a physician I had to become a people watcher…. or more accurately an observer of the people around me.  Even if you aren't medical people, I am sure many of you are as well…. but being very observant is a requirement for a physician because there are many signs of illness that can be observed just from observing a patient who we I am treating.  I always pay attention to how the patient I am consulting with walks, shakes my hand (their strength), and how well they care for themselves, the quality of their speech, whether they look well nourished, over-nourished or frail.  All of these individual observations and more, become automatic to me as a doctor. They help me diagnose and treat my patients without a stethoscope or even an x-ray… Today I want to talk about frailty, what it is, and what it means to your doctor and you as a patient. Frailty can be defined as the visible qualities of loss of muscle mass, bone mass, energy, as and strength, as well as thinning of the skin, kyphosis of the spine (standing with your head looking down and your shoulders rounded), slow movements, weakness of strength and voice.  Frailty is the visible sign of aging. The opposite of Frailty is the Quality of being robust. When we are young we are strong, energetic, our muscles are visible, our skin is clear and taught, our posture is straight and we appear healthy and strong….when we are young we are Robust!   Frailty is the quality of being old and weak, in a catabolic state (or a state of tissue breakdown and “shrinking”).  You can equate Frailty with aging, or physically being old. What does frailty mean to a doctor? When we take care of a patient who comes to us for the first time in a frail state we rule in or out a list of diseases of aging and physical problems. These include: Arthritis Osteoporosis Sarcopenia or severe loss of muscle mass and strength Inflammatory diseases like arthritis Heart disease Diabetes Dementia Inability to be independent Doctors must look for illness and decide on a treatment to remedy a disease, but frailty is not considered a disease that has a treatment.  It is a sign that a patient is going through the last stage of life.  Many studies have been done that equate frailty to a limited life span and a loss of quality of life, but no treatment has been employed by mainstream medicine to delay, avoid or treat frailty. Up to now this is all very depressing, however it is my well founded belief that the loss of testosterone  after age 45 in women and 55 in men is the first step toward frailty, however if  adequate testosterone is replaced soon after the symptoms of T deficiency starts, then frailty can be avoided as we age, and the eventuality of loss of quality of life will be delayed or avoided all together.  It is a fact that nothing other than the hormone testosterone can reverse frailty and stop it from progressing. With T treatment my patients increase their muscle mass, create stronger muscles, and improved their mental and physical stamina. To me this is such an easy one-hormone-answer to actually improve my patients lives, at any stage in the aging process, however the pharmaceutical companies that control American medicine much prefer to treat each symptom with a different drug.  There are millions of aging folks in nursing homes who could have maintained their independence, and avoided the use of many drugs if they were treated with testosterone before their frailty reduced their mobility so they need help to perform daily activities of living independently. Sadly, medicine in the US basically gives up on frail and aging patients and we doctors are taught to make frail patients “comfortable”, just treating their symptoms without hope of reversing frailty and the outcomes of that condition.  Of course, it is much healthier to prevent frailty by replacing the essential hormone testosterone early on, however your doctor will have to think out of the box to arrive at the Testosterone treatment, rather than follow the medical protocols that involve just keeping aging patients “comfortable”. Research studies and articles to be read by doctors like the recent one in the New England Journal of Medicine that draws a direct line between aging and frailty, but only concentrates on the fact that frailty portends early death and discussed the best ways to make patients comfortable dictated by the severity of frailty.  There is no treatment other than high protein diet and vitamins with physical therapy which will not “treat” this disease. I want to tell you about two very different patients in my practice.  The first is a very successful man in his late 70s who came to me seeking weight loss because he had been an athlete and still enjoyed playing golf, but he was complaining of weakness and other symptoms of frailty, in addition to looking borderline frail when he first came to me.  We did a body composition test, and he had a higher fat mass and a lower that ideal muscle mass which is the way frailty begins. We discussed the fact that weight loss (fat loss) obtained by more exercise and less carbohydrate in his diet might improve his Pre-diabetes and inflammation, but would not make him stronger, or increase his physical and mental stamina, in other words reverse his beginning frailty.  He chose to embark on an exercise-based weight loss program combined with a high protein low carb diet. In the end he did not take my advice about the best way to lose weight without losing muscle which would have been to add Testosterone and Metformin to his treatment plan, however he wanted to be the one directing his own care (he was a business man and not a doctor) without a basic knowledge of physiology, or  nutrition, or any training about aging and frailty. Let me note that if he was younger than 55, and he tried this weight loss program while he was making adequate Testosterone, he might have had a successful fat loss program and gained muscle density and strength while he lost fat, however, this gentleman is 78. You can guess the end of the story.  He did lose weight, however he lost as much muscle as fat and was even weaker after 6 months.  This is sometimes what happens when very successful people in one area of life think that makes them brilliant in all disciplines. Now, the flipside of the coin.  I will tell you about an 82-year-old doctor who came to me almost too late.  His much younger wife was already my patient, and she encouraged him to have a consult with me to see what I could do for him.  He had the right attitude, but was already frail, and I could feel the humorous bone of his arm, when I ushered his into my office for his consultation.  I explained what observing him and his lab told me more while he told me that he had almost every symptom of aging, and frailty.  He told me that he was an athlete in college and that he always had a lot of muscle, and he watched every day as his muscles “melted away”, despite his exercise daily.  He was frustrated and had trouble with his memory as well because he had lost his testosterone long ago and he had done well for as long as he had because he had eaten a nutritious diet, taken supplements and worked out daily. We discussed his other medical problems, and some treatments for them, additional supplements to assist in building muscle and bone strength. He came back 5 months later after he had his T pellets inserted and he walked in with confidence, and the difference in his muscle mass was visible!  He was no longer “frail looking”.  He told me he was thinking better, not completely yet, but his mind was getting progressively better.  He had lost fat and gained muscle. He had turned the clock back 15 or more years.  Testosterone in the right dose and delivery system can erase frailty and give a quality of life back to my patients who had no help from other doctors. Look around you if you aren't yet at the age that carries with it frailty  or if you are without Testosterone and are experiencing frailty…look at those around you in the doctor's office or when you are waiting to board a plane…look at the pre-borders who can't walk the length of the ramp to the airplane and see if they have the visible characteristics I am talking about.   If you are over 45 and female or 55 and male and not on Testosterone maybe you should consider having your testosterone replaced so you can keep your muscle mass and independence as long as you live.

Biohacking for Longevity: Extending Your Health Span. In this episode of "Leyla Weighs In," registered dietician and nutritionist Leyla Muedin discusses the concept of biohacking and its potential to extend lifespan and health span. Leyla explores various biohacking strategies such as diet optimization, regular physical activity, stress management, enhancing sleep quality, and maintaining strong social connections. She emphasizes the importance of epigenetics, targeted lifestyle changes, and advanced medical interventions like stem cell therapy. You will learn practical biohacking tips, including the benefits of intermittent fasting, the significance of exercise, and how to use wearable technology for health tracking. Leyla also highlights the role of supplements and personalized nutrition in promoting longevity, alongside maintaining good dental health and a sense of purpose. Through these combined efforts, Leyla aims to inspire listeners to not only live longer lives but to enjoy better health and vitality.

Dr. Sujatha Kekada is the Head Physician and Co-Founder of AmrtaSiddhi Ayurvedic Clinic in Ubud, Bali. She chats with Colette about inflammatory disorders in the urinary system and they discuss the following: The Ayurvedic perspective on the urinary system and the doshas involved. The root cause of inflammation. Dr. Sujatha covers the following disorders: Burning urination Urinary tract infections Cystitis Kidney infections Kidney stones Common causes of urinary tract infections. How the emotion of fear can play a role in these disorders. Tips to prevent these disorders from manifesting * Check out Dr. Sujatha's website here.... amrtasiddhi.com * Click here to learn more about discounted group Digestive Reset Cleanse starting March 28th, 2025 * Visit Colette's website www.elementshealingandwellbeing.com  Online consultations & Gift Vouchers Private at-home Digestive Reset Cleanse tailored to you Educational programs - Daily Habits for Holistic Health Have questions before you book? Book a FREE 15 min online Services Enquiry Call * Join the Elements of Ayurveda Community! * Stay connected on the Elements Instagram and Facebook pages. * Enjoy discounts on your favourite Ayurvedic products: Banyan Botanicals - enter discount code ELEMENTSOFAYURVEDA at checkout for 15% off your first purchase.** Divya's  - enter discount code ELEMENTSOFAYURVEDA15 at checkout for 15% off your first purchase.** Kerala Ayurveda - enter discount code ELEMENTS15 to receive 15% off your first purchase.** **Shipping available within the U.S. only. * Thanks for listening!  

In studio with Jon Justice. Rep Max Rymer, Kathryn Hideracker, AK Kamara in the final hour talking about Pyramid Structures, DFL gaslighting over GOP Sen Arrest and lots of Freedom Friday Talkbacks 

In Case No. CR01-24-31665, the defense has filed Motion in Limine #1 to exclude inflammatory evidence in the trial of Bryan Kohberger. The motion argues that certain evidence may unfairly prejudice the jury, inflaming emotions rather than contributing to a fair and impartial evaluation of the facts. The defense contends that such evidence lacks probative value and could lead to an unfair trial, potentially violating Kohberger's constitutional rights.The motion requests that the court carefully review and exclude any evidence deemed overly graphic, emotionally charged, or otherwise prejudicial. The defense emphasizes the importance of ensuring a trial based on facts and legal standards rather than emotional reactions. By filing this motion, Kohberger's legal team aims to prevent any undue influence on the jury and secure a fair judicial process.In Motions in Limine #2 and #3 in Case No. CR01-24-31665, Bryan Kohberger's defense seeks to exclude additional prejudicial evidence from trial. Motion #2 requests the exclusion of speculative or unreliable expert testimony, arguing that such testimony could mislead the jury and lacks a sufficient scientific basis. The defense contends that only properly vetted, methodologically sound expert opinions should be admitted to ensure a fair trial. Motion #3 seeks to bar any references to uncharged or unrelated bad acts allegedly committed by Kohberger. The defense argues that introducing such evidence would unfairly bias the jury, violating evidentiary rules that prohibit character attacks unrelated to the charges at hand. Both motions emphasize the necessity of maintaining a trial based strictly on admissible, fact-based evidence to ensure due process.to contact   me:bobbycapucci@protonmail.comsource:022425-Defense-Motion-inLimine-1-RE-Inflammatory-Evidence.pdf022425-Defense-Motion-inLimine-3-RE-Use-Term-Murder.pdf022425-Defense-Motion-inLimine-4-RE-Using-Terms-Psychopath-Sociopath.pdf

The Inflammatory Reset: My Experience Following the Protocol It's been a while since we've done a book club episode, and I'm excited to dive into The Inflammatory Reset by Dr. Josh Redd. This book is all about reducing chronic inflammation through diet, lifestyle changes, and functional medicine approaches. I've been following the protocol for at least 30 days - in the episode I'll share more about why.

In this episode of the Health Detective Podcast by Functional Diagnostic Nutrition, host Evan Transue, AKA Detective Ev, dives into the complexities of food sensitivity testing with a focus on the Mediator Release Test (MRT). Evan elaborates on the importance of understanding various immune responses to foods, differentiates between food allergies, intolerances, and sensitivities, and presents a strong case for using MRT testing. Listeners will also hear about the upcoming Holistic Health Week, featuring over 30 live interviews with health experts. Additionally, real-life client examples illustrate how pinpointing food sensitivities can significantly impact health and wellness.   Join us for FDNs biggest FREE event ever! 30+ speakers in one week, 100% live and free Q and A with the experts. Click here to register. Want to watch this episode on YouTube? Click here. Subscribe if you'd like to catch all new episodes live and participate with our guests directly. Not sure what you're looking for yet? Get access to FDN's best resources (both free and paid) at fdntraining.com/resources.

Join James Kustow, BMBS, MRCPsych, to learn about the emerging research that may explain ADHD's unexpected associations with inflammatory conditions like allergy and autoimmunity — and a surprisingly strong link with hypermobility syndrome. ADHD and Physical Health: More Resources Read: How ADHD Can Intensify Physical Health Conditions Free Download: Lifestyle Changes for Adults with ADHD Read: Chronic Fatigue Twice as Likely Among Children with ADHD Access the video and slides for podcast episode #545 here: https://www.additudemag.com/webinar/thyroid-adhd-inflammation-autoimmune-disease/ Thank you for listening to ADDitude's ADHD Experts podcast. Please consider subscribing to the magazine (additu.de/subscribe) to support our mission of providing ADHD education and support.